Clinical trials: Pancreatic Tumors
Pancreatic Cancer
Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer
This trial is a prospective, single-arm, single-center, phase II clinical study, mainly targeting subjects with locally advanced pancreatic cancer, to explore the efficacy and safety of adebrelimab combined with irinotecan…
- Trial name
- NCT06766019
- Testing
- Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
- Where
- China
- Volunteers
- 47 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced…
- Trial name
- NCT00016965
- Testing
- ixabepilone
- Where
- 95 sites in United States
- Sponsor
- SWOG Cancer Research Network
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Pancreatic Cancer
BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
The main purpose of this study is to see primarily if BYL719 is safe to be given to patients in combination with gemcitabine and nab-paclitaxel.
- Trial name
- NCT02155088
- Testing
- BYL719, Gemcitabine, (nab)-paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with conventional treatments having little impact on disease course.
- Conditions
- Pancreatic Adenocarcinoma Resectable, Pancreatic Adenocarcinoma Locally Advanced, Pancreatic Adenocarcinoma Metastatic
- Trial name
- NEOPAX-001 (NCT01715142)
- Testing
- Gemcitabine, Abraxane
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Jean-Luc Van Laethem
Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
The goal of this clinical trial is to learn whether the Ad5.F35-hGCC-PADRE vaccine is safe and can stimulate an immune response against gastrointestinal (GI) cancers in patients with pancreatic, colorectal, esophageal, gastric…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8
- Trial name
- NCT04111172
- Testing
- Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Pancreatic Cancer
The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
The purpose of the study is to evaluate the feasibility and acceptability of a remote nutrition coaching and monitoring intervention during the 12-weeks of active chemotherapy for borderline resectable and locally advanced…
- Trial name
- NCT06050395
- Testing
- Quality fo Life Questionnaire (FHSI), Vioscreen Food Frequency Questionnaire (FFQ), Educational Handouts
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreas Cancer, Pancreas Neoplasm
Patient-derived Organoids Drug Screen in Pancreatic Cancer
Few chemotherapeutic options exist for pancreatic cancer. Moreover, objective criteria are lacking for deciding which regimen is more beneficial for patient presenting with metastases at diagnosis.
- Conditions
- Pancreas Cancer, Pancreas Neoplasm, Pancreas Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT05351983
- Testing
- Surgical biopsy of tumoral tissue for organoid generation
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Prof. Dr. med. Dres. h.c. Jan Schmidt, MME
Pancreatic Cancer, Carcinoma
A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma
French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma.
- Trial name
- NEOPAN (NCT02539537)
- Testing
- Gemcitabine, Folinic Acid, 5-Fluoro-uracil
- Where
- 45 sites in France
- Volunteers
- 171 people
- Sponsor
- UNICANCER
Pancreatic Cancer
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
This study is an open-label, single-arm Phase II clinical study to evaluate the efficacy and safety of ivonescimab(AK112/SMT112) in combination with stereotactic body radiation therapy and chemotherapy in patients with pancreatic…
- Trial name
- NCT06491472
- Testing
- Ivonescimab, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Pancreatic Cancer
Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer
To assess the ability of a combination of updated and approved modalities in the treatment of first line pancreatic cancer patients to increase the time to Progression Free Survival
- Trial name
- NCT01760694
- Testing
- Multi-Modality; IORT, Surgery, Radiation, Chemotherapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Southwestern Regional Medical Center
Metastatic Pancreatic Cancer
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
- Trial name
- NCT00922896
- Testing
- Gemcitabine, Cisplatin, Erlotinib (Tarceva)
- Where
- 3 sites in South Korea
- Volunteers
- 22 people
- Sponsor
- Gyeongsang National University Hospital
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
- Trial name
- CAPAFOUR (NCT04990037)
- Testing
- CAN04, FOLFIRINOX
- Where
- 9 sites in France, Spain
- Volunteers
- 25 people
- Sponsor
- Cantargia AB
Solid Tumor, Adult, Lung Adenocarcinoma
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
To evaluate the safety and efficacy of T cell therapy with mutated TP53 R248Q specific TCR transduction in patients with advanced solid tumor expressing the TP53 R248Q mutation and the HLA-A*11:01 allele.
- Conditions
- Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer, Colorectal Cancer
- Trial name
- NCT06619886
- Testing
- Autologous, engineered T Cells targeting TP53 R248Q
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Pancreatic Cancer
Trabectedin in Treating Patients With Metastatic Pancreatic Cancer After First-Line Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- PACT-18 (NCT01339754)
- Testing
- trabectedin
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer, Surgery
Quality of Life in Elderly Patients After Pancreatic Cancer Surgery
Pancreatic cancer mainly affects the elderly, with over 85% of patients diagnosed after the age of 60 and over half after the age of 70.
- Conditions
- Pancreatic Cancer, Surgery, Elderly
- Trial name
- ADL_DPC_PA (NCT06079229)
- Testing
- Phone call
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Malignant Breast Neoplasm, Malignant Colorectal Neoplasm
18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
This early phase I trial studies how well 18F-fluoroazomycin arabinoside positron emission tomography (PET)-computed tomography (CT) works in diagnosing solid tumors.
- Conditions
- Malignant Breast Neoplasm, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03168737
- Testing
- Computed Tomography, Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)
10 Patients with Locally Advanced Pancreatic Cancer, no further responsive to neoadjuvant treatments but with a Stage-III disease will be submitted to imILT (Immunostimulating Interstitial Laser Thermotherapy).
- Trial name
- NCT02702986
- Testing
- immunostimulating Interstitial Laser Thermotherapy, Laser
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Universita di Verona
Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
The goal of this clinical trial is to test if the addition of botensilimab to standard chemotherapy improves the efficacy compared to just chemotherapy alone in participants with metastatic pancreatic cancer.
- Trial name
- NCT05630183
- Testing
- Botensilimab, Gemcitabine, Nab-paclitaxel
- Where
- 36 sites in United States
- Volunteers
- 81 people
- Sponsor
- Agenus Inc.
Borderline Resectable Pancreatic Cancer, High-Risk Resectable Pancreatic Cancer
Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC
This is a prospective, single-center, single-arm phase 2 study evaluating the efficacy and safety of neoadjuvant surufatinib plus iparomlimab and tuvonralimab injection and nab-paclitaxel/gemcitabine chemotherapy in patients with…
- Trial name
- ZSPAC-22 (NCT07833241)
- Testing
- Surufatinib Plus Iparomlimab and Tuvonralimab and AG Chemotherapy, Gemcitabine plus Capecitabine, Modified FOLFIRINOX
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai Zhongshan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.